EpitoPredikt and EpitoGen® Technologies have been applied in the development of an epitope-based SARS-CoV-2 serology test with 99% accuracy
In the development of this precise serology test, the following epitope-based approach was employed:
Step 1- Identification of immunodominant epitopes using EpitoPrediktTM
Our AI software identified immunodominant regions “epitopes” within the SARS-CoV-2 viral proteins. The immunodominant epitopes are the specific viral elements that trigger the body’s antibody defence systems.
Step 2- Display epitopes on EpitoGen® scaffold
Our team displayed selected epitopes on the scaffold system and screened serum and plasma taken from patients, who tested positive for SARS-CoV-2. Seasonal coronavirus positive sera and pre-COVID sera were used as negative controls. The best combination of epitopes was identified after testing each individually and then selecting those with the best sensitivity and specificity.
Step 3- Multiplex selected epitopes
The best combination of epitopes was fused together to create a chimeric antigen, whereby the sensitivity of the epitopes is combined to create a novel epitope-based assay. The AI-assisted EpitoGen® bio-scaffold has created a game-changing platform for serology diagnostics due to its superior performance and flexibility. This technology has the capacity to combine the performance of multiple immunodominant epitopes, thereby enhancing the signal-to-noise ratio and eliminating cross-reactive epitopes to ensure specificity. Using this approach, prevalent SARS-CoV-2 variants are easily incorporated into the test, further boosting its sensitivity.
The success of this project was published by the University of Aberdeen News.
Our EpitoPrediktTM and EpitoGen® technologies emerged as disruptive platforms that will play a pivotal role in advancing the response to future pandemics and endemics. Our game-changing technologies have demonstrated the potential to change the trajectory of global recovery from the COVID-19 pandemic. Notably, the innovation and advancement in the performance of these novel technologies ensure affordable, accurate testing for many auto-immune conditions. Therefore, such novel antibody tests will be provide a mechanism for enhancing both the diagnostics and the health sectors, which is something fundamental during these challenging times.